Follow the latest UNITEDHEALTH GROUP INCORPORATED (Delaware) (UNH) news and market headlines alongside the live UNH price. Stay informed on what's moving UNH.
UnitedHealth Group (NYSE:UNH) has outperformed the market over the past 20 years by 2.67% on an annualized basis producing an average annual return of 11.45%. Currently, UnitedHealth Group has a market capitalization of
UnitedHealth Group (UNH) reported Q3 2026 adjusted EPS of $4.69, beating consensus estimates of $4.12, with a 60.6% year-over-year increase. The company raised its 2026 adjusted EPS guidance to at least $20.5 from the previous range of $19.5-$20, driven by improved medical cost management and strong performance from Optum Insight and Optum Rx. Despite a slight revenue decline of 0.4% year-over-year to $112.7 billion, the company improved its medical care ratio to 88.4% and generated strong operating cash flows of $25.1 billion in the first nine months of 2026.
UnitedHealth Group has demonstrated strong management performance in correcting 2025 miscalculations, with earnings jumping 60% and guidance raised for the third time in the year. The article examines whether the stock remains a good investment opportunity despite its recent strong performance.
CVS Health announced plans to separate into two independent publicly traded companies by mid-2028: one retaining Aetna, Caremark, and care operations, and another housing retail pharmacies and MinuteClinic. The split aims to improve capital allocation and operating flexibility, though it carries execution risks, restructuring costs, and potential dis-synergies during the transition period.
Humana Inc. has launched a new oncology care model in partnership with Evolent Health and American Oncology Network across eight states. The initiative streamlines prior authorization for qualifying practices, uses EHR analytics and provider scorecards to promote evidence-based cancer treatment, and aims to improve care coordination while reducing specialty care spending. HUM stock has rallied 82.2% over the past year but trades at a premium valuation of 29.08x forward P/E versus the industry average of 15.72x.
CVS Health is entering a more constructive earnings phase as Aetna's medical benefit ratio improves, pharmacy operating income rises 10.6%, and operating cash flow reaches $15.32 billion. However, persistent pressure from pharmacy benefit management, medical membership declines, and reimbursement headwinds keep execution risk elevated through 2027.
UnitedHealth Group has raised its 2026 earnings guidance for the third time this year, with adjusted EPS now targeted at $20.50, up from $17.75 in January. The company's turnaround is gaining momentum, driven by operational improvements in Optum Health and better medical cost management. Analysts project the stock could reach between $444 and $672 by 2029 based on 13-16% annual earnings growth, though regulatory scrutiny and rising medical costs remain risks.
Browse other US stocks in the same sector as UNITEDHEALTH GROUP INCORPORATED (Delaware)
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to UNH, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.